This company listing is no longer active
Mallinckrodt Past Earnings Performance
Past criteria checks 0/6
Key information
-22.4%
Earnings growth rate
-21.5%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | -8.7% |
Return on equity | -358.7% |
Net Margin | -32.7% |
Last Earnings Update | 01 Apr 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Mallinckrodt makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
01 Apr 22 | 2,142 | -699 | 592 | 176 |
31 Dec 21 | 2,209 | -723 | 571 | 205 |
24 Sep 21 | 2,294 | -674 | 615 | 231 |
25 Jun 21 | 2,486 | -213 | 653 | 250 |
26 Mar 21 | 2,106 | -1,057 | 689 | 280 |
25 Dec 20 | 2,213 | -970 | 769 | 291 |
25 Sep 20 | 2,336 | -1,976 | 788 | 307 |
26 Jun 20 | 2,381 | -2,169 | 791 | 345 |
27 Mar 20 | 3,038 | -1,219 | 825 | 342 |
27 Dec 19 | 3,163 | -1,007 | 828 | 349 |
27 Sep 19 | 3,193 | -3,565 | 847 | 368 |
28 Jun 19 | 3,249 | -3,449 | 874 | 351 |
29 Mar 19 | 3,251 | -3,446 | 881 | 364 |
28 Dec 18 | 3,216 | -3,622 | 878 | 361 |
28 Sep 18 | 3,842 | 1,841 | 906 | 393 |
29 Jun 18 | 3,642 | 1,780 | 968 | 354 |
30 Mar 18 | 3,417 | 1,795 | 967 | 314 |
29 Dec 17 | 3,222 | 1,771 | 977 | 277 |
29 Sep 17 | 2,591 | -150 | 1,066 | 210 |
30 Jun 17 | 2,877 | -93 | 1,075 | 231 |
31 Mar 17 | 3,144 | 65 | 1,084 | 254 |
30 Dec 16 | 3,400 | 208 | 1,078 | 267 |
30 Sep 16 | 3,381 | 489 | 929 | 261 |
24 Jun 16 | 3,686 | 522 | 1,021 | 213 |
25 Mar 16 | 3,593 | 381 | 1,036 | 197 |
25 Dec 15 | 3,494 | 335 | 1,062 | 196 |
25 Sep 15 | 2,923 | 235 | 897 | 203 |
26 Jun 15 | 2,795 | 38 | 847 | 211 |
Quality Earnings: MNKK.Q is currently unprofitable.
Growing Profit Margin: MNKK.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MNKK.Q is unprofitable, and losses have increased over the past 5 years at a rate of 22.4% per year.
Accelerating Growth: Unable to compare MNKK.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MNKK.Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.9%).
Return on Equity
High ROE: MNKK.Q has a negative Return on Equity (-358.72%), as it is currently unprofitable.